



---

## Surveying Pharmacovigilance Tactics in India: Current Landscape and Future Outlook

Fauzia Shakir\*, Dr. Gaurav Bhaduka, Dr. Mukesh Bansal

\*Mahatma Gandhi College of Pharmaceutical Sciences, Sitapura, Jaipur.

Mail ID: [fauziashakir199@gmail.com](mailto:fauziashakir199@gmail.com)

---

**Abstract:** The pharmacovigilance has undergone significant development in India, with a primary focus on ensuring the safety and effectiveness of pharmaceutical products. This analysis examines current PV strategies, including regulatory frameworks, encountered difficulties, and progress made. It explores the roles played by different stakeholders—regulatory bodies, pharmaceutical companies, healthcare providers, and patients—in shaping PV practices. Additionally, it investigates innovative approaches and technological advancements aimed at improving PV standards. The study concludes with potential trajectories and recommendations to strengthen statewide patient safety through an enhanced PV infrastructure. This discussion aims to improve understanding of PV in India by addressing regulatory frameworks, methodologies, stakeholder involvement, challenges, advancements and future directions. By offering valuable insights into these aspects of pharmacovigilance in India, this contribution caters to the informational needs of policymakers "healthcare professionals", "pharmaceutical firms", "and other stakeholders committed to upholding the integrity "safety" of medical interventions."

**Keywords** Pharmacovigilance, Adverse Drug Reactions, Regulatory Framework, Healthcare, Drug Safety, Pharmacovigilance Infrastructure, Reporting Systems

---

### Introduction

Adverse drug reactions are a significant burden on global healthcare, leading to illness and death. Many ADRs remain unreported or unnoticed in communities with limited resources. Pharmacovigilance addresses this by "monitoring and reporting drug safety". [1] It originated from the thalidomide tragedy in the 1960s [2,3], shifting healthcare focus to post-market drug monitoring for harm prevention. "Its objectives include early detection of adverse effects, assessing medication risks and benefits, and preventing harm through robust reporting systems involving healthcare providers, patients, and pharmaceutical companies." [4] Over time, pharmacovigilance has evolved to include proactive strategies like risk management plans and advanced technologies such as data mining for signal detection. Globalization has led to efforts for harmonization and international collaborations "aimed at ensuring consistent standards and timely exchange of safety information" to enhance pharmacovigilance effectiveness worldwide. [1]

### Background

Pharmacovigilance, or PV, is essential for ensuring the safe and efficient use of pharmaceuticals. Stemming from incidents such as the thalidomide disaster, PV focuses on identifying and preventing adverse effects. [4,5] The World Health Organization initiated global efforts by launching International Drug Monitoring programs in 1968 to establish a network of PV centers for worldwide data collection and analysis. [6,7] Regulatory bodies like the FDA and EMA maintain high standards for PV operations to ensure ongoing medication safety monitoring.[7,8]



Technological advancements such as electronic databases and AI have transformed PV methods by utilizing data mining and social media for real-time insights.[9] As healthcare continues to evolve with new medications emerging, PV remains crucial in drug research, regulation, and post-marketing surveillance - contributing significantly to improving global public health.

### Overview of Pharmacovigilance

Pharmacovigilance is crucial in healthcare as it ensures the safety of pharmaceuticals post-market. It encompasses monitoring, identifying, assessing, and mitigating adverse effects. [4,10] Collaboration among healthcare experts, regulatory authorities, and patients is essential for comprehensive data collection on medication use and side effects. [3,10,11] Various reporting methods and databases aid in monitoring adverse drug reactions and identifying patterns. The process involves gathering data from diverse sources to evaluate causality, severity, and frequency of adverse events while informing regulatory decisions.[11] Continuous monitoring is vital for detecting rare or long-term adverse effects not evident during premarketing stages. Pharmacovigilance is essential for ensuring medication safety throughout their lifecycle in modern healthcare systems. [4,5]

### Significance of pharmacovigilance in India

Pharmacovigilance holds significant importance in India, where a large population relies on pharmaceuticals. Its role encompasses the detection, assessment, and prevention of adverse drug effects to ensure the availability of safe medications in the market. Here's why it matters:(1) *Patient Safety*: Pharmacovigilance monitors adverse drug reactions to safeguard patients from potential harm. [4,12] (2) *Public Health*: It identifies and addresses safety concerns, fostering well-being and instilling trust in healthcare. (3) *Regulatory Compliance*: It is mandated by regulatory bodies like CDSCO to uphold safety standards. [12,13] (4) *Global Market Access*: Adherence to international standards enhances the reputation of Indian pharmaceuticals globally. (5) *Early Risk Detection*: This enables prompt regulatory action to mitigate potential harm associated with drugs. (6) *Education and Awareness*: Raises awareness about responsible medication use along with reporting adverse events. [12,13,14] Through promoting transparency and accountability, pharmacovigilance protects Indian citizens' health while strengthening the overall healthcare system.

### Objectives of the Review

This research delves into the field of pharmacovigilance in India, with the goal of enhancing public health within the rapidly growing pharmaceutical industry. Objectives encompass evaluating existing practices, identifying regulatory deficiencies, assessing the effectiveness of reporting mechanisms, analyzing infrastructure, examining this research delves into the field of pharmacovigilance in India, with the goal of enhancing public health within the rapidly growing pharmaceutical industry. stakeholder involvement and presenting recommendations for improvement. [4,12,14]

### Historical Perspective of Pharmacovigilance in India

The history of pharmacovigilance in India dates to the 1980s when concerns about drug safety led to the establishment of the Adverse Drug Reaction Monitoring Centre by the Indian Pharmacopoeia Commission. [14,15] This initiative evolved into the National Pharmacovigilance Programme, laying a strong foundation for systematic monitoring of adverse drug reactions. [12,16] In 2004, the Indian government launched the Pharmacovigilance Programme of India to enhance ADR reporting, detection, and prevention. [4,5,16] This initiative, led by the Indian Pharmacopoeia Commission, established regional and zonal monitoring centers across country. India's pharmacovigilance efforts gained momentum in 2005 when it aligned with global initiatives such as World Health Organization's Programme for International Drug Monitoring, adopting internationally recognized standards and fostering collaboration with other countries. [12,14,17] Throughout the 2010s, regulatory reforms led by Central Drugs Standard Control Organization strengthened pharmacovigilance practices. It included issuing guidelines and establishing Pharmacovigilance Advisory Committee for strategic guidance. [17,18] There was also significant expansion on pharmaceutical alerts during same decade. PvPI increased outreach to healthcare professionals, patients, and consumers.[4] It aimed at enhancing skills among



health care professionals. The digital transformation witnessed advancement in use data analytics plays, as well as adoption of digital platforms that streamlined ADR reporting. [17] Mobile applications, online systems. Adoption of artificial intelligence has shown promise for improved signaling detection risk assessment. India emerged globally leader participation in world forums. [12-18] Other countries seek expertise targeted collaborative research captivity initiatives worldwide.

### **Regulatory Framework of Pharmacovigilance in India**

In India, the Central Drugs Standard Control Organization (CDSCO) within the Ministry of Health and Family Welfare is responsible for overseeing pharmacovigilance, which monitors adverse drug reactions (ADRs). Established in 2010, the Pharmacovigilance Programme of India (PvPI) forms the core of this system, encouraging ADR reporting nationwide. PvPI collaborates with healthcare providers, pharmaceutical companies, and regulatory bodies to collect and analyze ADR data. [19,20] India aligns with global standards, particularly those set by the World Health Organization (WHO), to ensure pharmaceutical quality, safety, and efficacy. [12,19] The regulatory framework for pharmacovigilance has evolved significantly, emphasizing detection, assessment, understanding, and prevention of adverse effects and drug-related issues.

#### **Key Points:**

1. CDSCO: Oversees drug approval and monitoring, ensuring drug safety, efficacy, and quality.
2. Drug and Cosmetics Act (DCA) and Rules: Provides the legal basis for drug regulation, empowering CDSCO.
3. PvPI: Established by CDSCO in 2010 to monitor medicine safety through ADR reporting. [12-17]
4. National Pharmacovigilance Advisory Committee (NPAC): Guides PvPI with expert input.
5. Guidelines and Regulations: Issued by CDSCO to ensure compliance and cover ADR reporting, risk management, etc.
6. International Collaboration: Partnerships with WHO and UMC enhance pharmacovigilance practices.
7. Regulatory Inspections and Audits: CDSCO ensures compliance through inspections focusing on pharmacovigilance.
8. Post-Marketing Surveillance: Mandatory studies to monitor drug safety post-approval.
9. Continuous Improvement: CDSCO and PvPI strive for better systems and capacity building through feedback and training initiatives. [15-19]

### **Overview of regulatory bodies and their roles**

Various regulatory bodies oversee pharmacovigilance to ensure drug safety and public health. Key organizations include the Food and Drug Administration, European Medicines Agency, World Health Organization, Pharmacovigilance Risk Assessment Committee, National Competent Authorities, and Pharmaceutical Industry. These agencies collaborate to safeguard public health through comprehensive pharmacovigilance efforts. [6]

### **Current pharmacovigilance regulations and guidelines**

In India, pharmacovigilance regulations are based on the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. These laws require pharmaceutical companies to report adverse drug reactions to the Central Drugs Standard Control Organization, which oversees these activities in collaboration with the Pharmacovigilance Programme of India. [14,19] A significant development occurred in 2010 when the Pharmacovigilance Guidance Document was introduced, outlining steps for establishing pharmacovigilance systems including appointing a qualified person responsible for pharmacovigilance and submitting periodic safety update reports. [21] In 2013, Schedule Y was amended to include pharmacovigilance data in clinical trial applications from early stages of drug development. India has aligned its regulations with international standards by joining the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use and adopting ICH guidelines like ICH E2B(R3) to enhance global collaboration. [19,21] Initiatives such as National Coordination Centre for Pharmacovigilance Programme of India have strengthened pharmacovigilance efforts.



### Compliance requirements for pharmaceutical companies

Compliance requirements for pharmaceutical companies in India are crucial to uphold medication safety and effectiveness. These encompass several key areas: obtaining Drug Manufacturing Licenses from the CDSCO, adhering to Good Manufacturing Practices (GMP), conducting rigorous Quality Control Testing, following Clinical Trials Regulations including DCGI approval, obtaining Drug Registration and Approval, ensuring Packaging and Labeling Compliance as per Drugs and Cosmetics Act, establishing Pharmacovigilance systems, adhering to Marketing and Advertising Regulations, complying with Price Control regulations set by NPPA, and respecting Intellectual Property Rights (IPR) Protection. [23,24] These measures collectively ensure the integrity and efficacy of pharmaceutical products in India.

### Pharmacovigilance Infrastructure in India

India's pharmacovigilance infrastructure is crucial for ensuring medication safety nationwide. Through regulatory frameworks and collaboration among government bodies, pharmaceutical companies, and healthcare professionals, India's system effectively monitors, assesses, and prevents adverse drug reactions. The National Coordination Centre for Pharmacovigilance Programme of India (PvPI) and its regional centers signify the nation's dedication to strong pharmacovigilance practices.[25]

### National Pharmacovigilance Program of India (PvPI)

India's National Pharmacovigilance Program (PvPI) plays a crucial role in monitoring adverse drug reactions (ADRs) nationwide. Through Regional Pharmacovigilance Centers (RPCs) and Adverse Drug Reaction Monitoring Centers (AMCs), PvPI promotes collaboration among healthcare professionals, regulators, and the pharmaceutical industry. [12,26] Its proactive approach and improved data management contribute to enhancing drug safety standards and raising awareness of pharmacovigilance across India.

### Role of Pharmacovigilance Centers and Regional Centers in India

In India, pharmacovigilance centers play a crucial role in gathering, analyzing, and sharing information on drug safety with healthcare providers, regulators, and the public. They help identify potential risks associated with medications, aiding in early detection and prevention of adverse effects. Regional centers extend this effort by creating a network for surveillance and collaboration across various regions. See [table:1](#) for a summary of their roles.

**Table 1:** Roles of Pharmacovigilance Centers and Regional Centers in India [27-31]

Role	Description
<b>Safety Monitoring Reporting and Analysis</b>	<ul style="list-style-type: none"> <li>monitoring the safety of pharmaceutical products, including drugs, vaccines, and medical devices, post their approval and entry into the market.</li> <li>for collecting, collating, and reporting adverse events associated with medicines and medical products.</li> <li>collection of data from healthcare professionals, patients, and other sources, followed by thorough analysis to identify potential risks and ensure patient safety.</li> </ul>
<b>Regulatory Compliance</b>	<ul style="list-style-type: none"> <li>ensure compliance with regulatory requirements set by the CDSCO and other regulatory bodies.</li> <li>help pharmaceutical companies adhere to reporting</li> </ul>
<b>Capacity Building</b>	<ul style="list-style-type: none"> <li>actively engage in capacity building activities like enhancing the knowledge and skills of healthcare professionals, regulatory authorities, and other stakeholders involved in pharmacovigilance activities.</li> <li>includes training programs, workshops, and seminars to promote a culture of drug safety and adverse event reporting.</li> </ul>
<b>Regional Outreach</b>	<ul style="list-style-type: none"> <li>role in extending pharmacovigilance activities to various geographic regions within India.</li> <li>facilitate decentralized reporting and ensure that adverse event data is captured comprehensively from diverse populations across the country.</li> </ul>



---

<b>Collaboration and Networking</b>	<ul style="list-style-type: none"> <li>• collaboration among Pharmacovigilance Centers, Regional Centers, academic institutions, healthcare organizations, and international pharmacovigilance networks strengthens the pharmacovigilance infrastructure in India.</li> </ul>
<b>Public Awareness and Education</b>	<ul style="list-style-type: none"> <li>• take initiatives to raise public awareness about the importance of pharmacovigilance and encourage active participation in reporting adverse events.</li> <li>• public education campaigns, informational materials, and helplines are utilized to empower patients and healthcare consumers to report any suspected adverse reactions they experience.</li> </ul>
<b>Continuous Improvement</b>	<ul style="list-style-type: none"> <li>• pharmacovigilance in India is evolving, with ongoing efforts to enhance the efficiency, effectiveness, and transparency of the pharmacovigilance system.</li> <li>• continuous evaluation, feedback mechanisms, and implementation of best practices contribute to the evolution of Pharmacovigilance Centers and Regional Centers in India.</li> </ul>

---

### Pharmacovigilance activities at healthcare institutions and pharmaceutical companies

Professionals carefully monitor and record adverse drug reactions, using online platforms and hotlines to gather data swiftly. Pharmaceutical companies in India follow strict regulations, employ dedicated teams and advanced software for reporting adverse events, conducting post-marketing studies to ensure product safety. [17]

### Pharmacovigilance Reporting Systems and Tools

In conjunction with PvPI, various tools and platforms have been developed to streamline pharmacovigilance reporting processes. Online reporting portals, such as the Vigiflow system, provide healthcare professionals, patients, and pharmaceutical companies with user-friendly interfaces to submit ADRs efficiently.[32] These platforms ensure seamless communication and data sharing between stakeholders, enabling prompt identification and response to emerging safety concerns.

### Adverse Drug Reaction (ADR) reporting mechanisms

ADR reporting mechanisms are essential components of Pharmacovigilance Reporting Systems, crucial for ensuring pharmaceutical product safety post-market approval. [2,33] These mechanisms enable individuals, including healthcare professionals and patients, to report adverse reactions, contributing to ongoing safety monitoring. Pharmaceutical companies use various data sources, such as spontaneous reports and clinical trials, to assess drug safety continuously.

### Integration of technology in pharmacovigilance

The integration of technology into pharmacovigilance in India has transformed the landscape of drug safety monitoring and regulatory oversight. Electronic reporting systems, mobile applications, data analytics, social media monitoring, integration with electronic health records, and telemedicine services have all been embraced by the sector to adopt more efficient and patient-centric approaches. [34-36] Training programs and clear regulatory guidelines ensure confidence in these digital solutions while collaborative efforts foster successful integration. [35,37] This technological shift not only simplifies reporting but also improves the identification of adverse drug reactions through advanced analytics, empowering regulators to effectively prioritize resources and make informed decisions for public health protection. [37]

### Challenges and opportunities in data collection and analysis

In the dynamic field of pharmacovigilance in India, collecting and analyzing data presents various challenges and opportunities. [13,22] Ensuring the safety and effectiveness of pharmaceutical products in the market is a top priority. The sheer volume and diversity of data from different sources create logistical obstacles such as standardization issues and data fragmentation. Innovative approaches are necessary to effectively manage this wealth of information. Challenges include maintaining data quality, privacy, and ethics; meanwhile, opportunities arise from advanced analytics and machine learning for valuable insights. [38-40] Additionally, while digital platforms provide unprecedented data access, robust cybersecurity measures are crucial. Collaborative efforts



across disciplines play a vital role by combining expertise in data science with domain knowledge and ethical frameworks.[39] Successfully navigating these challenges and opportunities has the potential to revolutionize industries, drive innovation, and enhance global decision-making processes.

### Challenges in Pharmacovigilance Implementation

Here are some of the key hurdles faced in the effective execution of pharmacovigilance are: (a) *Underreporting*: Many adverse drug reactions (ADRs) remain unreported due to factors like lack of awareness, time constraints, or uncertainty about causality, leading to incomplete safety profiles for drugs and potential risks to patients.[41-43] (b) *Data Quality*: The effectiveness of pharmacovigilance hinges on high-quality data collection, but issues like incomplete or inaccurate information in adverse event reports can compromise the system's efficacy.[38,39] (c) *Signal Detection*: Identifying safety signals amidst vast data volumes poses a significant challenge, necessitating robust methods and algorithms for timely detection of emerging safety concerns.[17] (e) *Regulatory Compliance*: Meeting pharmacovigilance regulations demands substantial resources and expertise, particularly for companies operating across districts with varying regulatory standards.[44] (f) *Resource Constraints*: Many healthcare systems, especially in low- and middle-income countries, face limitations in investing in pharmacovigilance due to resource constraints, leading to surveillance coverage gaps and delayed responses to safety issues.[15,17]

### Pharmacovigilance in Specific Therapeutic Areas

Pharmacovigilance is increasingly vital in India across various therapeutic domains as the pharmaceutical sector expands and regulations tighten. Specific areas like oncology, psychiatric disorders, infectious diseases, cardiovascular diseases, diabetes management, respiratory disorders, gastrointestinal conditions, neurological disorders, rheumatological conditions, and obstetrics/gynecology highlight the crucial role of pharmacovigilance. [4,15,17] In each domain, close monitoring for adverse reactions, drug interactions, and safety concerns is imperative. Key activities include adverse event reporting, signal detection, risk assessment, management, and dissemination of safety information to healthcare providers and the public. [15,21]

### Pharmacovigilance strategies for infectious diseases

These encompass robust surveillance systems to monitor adverse drug reactions (ADRs), proactive risk assessment, and swift communication channels for emerging safety concerns. [19,46] Key approaches include comprehensive monitoring of ADRs related to antimicrobial agents and vaccines, proactive signal detection, and collaboration among regulatory agencies, healthcare providers, and research institutions. [2] Continuous risk-benefit assessment, timely reporting, and integration of real-world evidence enhance pharmacovigilance efforts. Educational initiatives aim to raise awareness among healthcare professionals and the public. Employing advanced data analytics and artificial intelligence aids in identifying safety trends. Continuous evaluation and adaptation of strategies are crucial for addressing evolving challenges in infectious diseases and safeguarding global population health. [47,48]

### Monitoring adverse events in oncology drugs

Monitoring adverse events in oncology drugs is crucial to ensure patient safety and to assess the overall benefit-risk profile of these medications. [45] Here are the steps typically involved in this process:

1. Define Adverse Events (AEs)
2. Identify Key Parameters
3. Establish Monitoring Protocols
4. Training and Education
5. Implement Surveillance Systems
6. Regular Monitoring
7. Adverse Event Reporting
8. Assessment and Analysis
9. Risk Management Strategies



## 10. Communication and Feedback

### Advancements in Pharmacovigilance Practices

Pharmacovigilance practices have seen significant advancements driven by various factors, including technological innovations, regulatory requirements, and evolving healthcare landscapes.[9,49,50] Key developments include the utilization of big data and artificial intelligence for faster detection of adverse drug reactions (ADRs) and emerging safety concerns, enhanced data collection methods through electronic health records (EHRs) and mobile health technologies, integration of real-world evidence (RWE) to complement clinical trial data, collaborative networks and data sharing initiatives to promote global pharmacovigilance standards, patient-centric approaches through engagement platforms and social media listening, initiative-taking risk management strategies such as Risk Evaluation and Mitigation Strategies (REMS), and regulatory framework enhancements like the European Union's Pharmacovigilance Risk Assessment Committee (PRAC) and the FDA's Sentinel Initiative. [9,39,51,52] These advancements collectively aim to optimize drug safety surveillance and risk communication throughout the medication lifecycle.

### Future Outlook and Recommendations

In recent years, India has witnessed significant strides in its pharmaceutical sector, emerging as a global hub for drug manufacturing and research. With this growth comes the imperative to ensure the safety and efficacy of pharmaceutical products.[53] As India continues to expand its pharmaceutical industry, it must bolster its regulatory oversight to meet evolving challenges and ensure the highest standards of pharmacovigilance.[54]

#### Outlook: [39,38]

- Technological Advancements
- International Collaboration
- Patient-Centric Approach
- Enhanced Regulatory Framework
- Capacity Building

#### Recommendations: [11]

- Establishment of a Centralized Pharmacovigilance Authority
- Mandatory Adverse Event Reporting
- Public Awareness Campaigns
- Regular Pharmacovigilance Audits
- Continuous Evaluation and Adaptation

### Conclusion

Assessment of pharmacovigilance strategies in India revealed numerous significant conclusions. It examines the present state of pharmacovigilance methods in the nation, offering light on existing tactics and their efficacy. likewise, the study gives insights into the future of pharmacovigilance in India, highlighting possible areas for development and innovation. Improving legal frameworks, encouraging stakeholder participation, and investing in cutting-edge technology are critical steps towards accomplishing this aim. Furthermore, prioritizing pharmacovigilance education and training programs can help enhance the monitoring system by allowing for early detection and management of adverse drug reactions. Despite significant progress in improving pharmacovigilance methodology, persistent stakeholder participation, investment in technology infrastructure, and capacity-building efforts are required to develop pharmacovigilance systems.

### References

- [1]. Najafi, Sheyda. "Importance of pharmacovigilance and the role of healthcare professionals." J Pharmacovigil 6.01 (2018): 1-2.



- [2]. NAQ, DSAD. "Adverse Drug Reactions and Pharmacovigilance: A Narrative Mini-review of Relevant Literature." - 2016
- [3]. Huysentruyt, Kristof, et al. "Validating intelligent automation systems in pharmacovigilance: insights from good manufacturing practices." *Drug Safety* 44 (2021): 261-272.
- [4]. Bihan, Kévin, et al. "Uses of pharmacovigilance databases: an overview." *Therapies* 75.6 (2020): 591-598.
- [5]. Waller, Patrick, and Mira Harrison-Woolrych. *An introduction to pharmacovigilance*. John Wiley & Sons, 2017.
- [6]. Peters, Tanja, et al. "Effective pharmacovigilance system development: EFPIA-IPVG consensus recommendations." *Drug safety* 44 (2021): 17-28.
- [7]. World Health Organization. "International standards for the treatment of drug use disorders: Revised edition incorporating results of field-testing." (2020).
- [8]. Alshammari, Thamir M., Khalidah A. Alenzi, and Sondus I. Ata. "National pharmacovigilance programs in Arab countries: A quantitative assessment study." *Pharmacoepidemiology and drug safety* 29.9 (2020): 1001-1010.
- [9]. Kugener, Veronique F., et al. "Enhancing pharmacovigilance from the US experience: current practices and future opportunities." *Drug safety* 44.8 (2021): 843-852.
- [10]. Hussain, Rabia, et al. "Exploring healthcare professionals' knowledge, attitude, and practices towards pharmacovigilance: a cross-sectional survey." *Journal of pharmaceutical policy and practice* 14.1 (2021): 5.
- [11]. Nisa, Zaka Un, Ayesha Zafar, and Farooq Sher. "Assessment of knowledge, attitude and practice of adverse drug reaction reporting among healthcare professionals in secondary and tertiary hospitals in the capital of Pakistan." *Saudi Pharmaceutical Journal* 26.4 (2018): 453-461.
- [12]. Jose, Jobin, and Naziya Refi Rafeek. "Pharmacovigilance in India in comparison with the USA and European Union: Challenges and perspectives." *Therapeutic innovation & regulatory science* 53.6 (2019): 781-786.
- [13]. Kalaiselvan, Vivekanandan, Prasad Thota, and Gyanendra Nath Singh. "Pharmacovigilance Programme of India: Recent developments and future perspectives." *Indian journal of pharmacology* 48.6 (2016): 624-628.
- [14]. Amale, Prashant N., et al. "Pharmacovigilance process in India: An overview." *J Pharmacovigil* 6.2 (2018): 259.
- [15]. Sangita Fulchand Pawar and Vikram Limbaji Musale (2020); PHARMACOVIGILANCE: A REVIEW *Int. J. of Adv. Res.* 8 (Jan). 235-243
- [16]. Gadhade, Jyoti B., et al. "Pharmacovigilance programme of India: revival of the renaissance." (2018).
- [17]. Mishra, Preti, et al. "A Review on Pharmacovigilance Process In India." *Asian Journal of Pharmaceutical Research and Development* 8.3 (2020): 190-195.
- [18]. Sethi, Manoj Kumar, and P. Ushashree. "Pharmacovigilance: Challenges in India." *J Pharmacovigil* 4.1 (2016): 1000194.
- [19]. Thota P, Thota A, Medhi B, Sidhu S, Kumar P, Selvan VK, Singh GN. Drug safety alerts of pharmacovigilance programme of India: A scope for targeted spontaneous reporting in India. *Perspect Clin Res.* 2018 Jan-Mar;9(1):51-55. doi: 10.4103/picr.PICR\_29\_17. PMID: 29430420; PMCID: PMC5799955.
- [20]. Ghosh, Anushka#; Choudhary, Gajendra1; Medhi, Bikash1. The pivotal role of artificial intelligence in enhancing experimental animal model research: A machine learning perspective. *Indian Journal of Pharmacology* 56(1):p 1-3, Jan–Feb 2024. | DOI: 10.4103/ijp.ijp\_81\_24
- [21]. Patil, Jagadevappa. "Journal of Pharmacovigilance." (2016).
- [22]. Brahmachari, Ballari; Fernandes, Melanie; Bhatt, Arun. Pharmacovigilance for clinical trials in India: Current practice and areas for reform. *Perspectives in Clinical Research* 2(2):p 49-53, Apr–Jun 2011. | DOI: 10.4103/2229-3485.80366





- [23]. Brody, Tom. *Clinical trials: study design, endpoints and biomarkers, drug safety, and FDA and ICH guidelines*. Academic press, 2016.
- [24]. Agarwal, Nidhi B., and Manoj Karwa. "Pharmaceutical regulations in India." *Pharmaceutical Medicine and translational clinical research*. Academic Press, 2018. 215-231.
- [25]. Kumar, S. & ., Badruddeen & Singh, S.P.. (2016). Pharmacovigilance: An inevitable path towards drug safety in India. *International Research Journal of Pharmacy*. 7. 1-7. 10.7897/2230-8407.0710113.
- [26]. Suke, S. G., Kosta, P., & Negi, H. (2015). Role of Pharmacovigilance in India: An overview. *Online Journal of Public Health Informatics*, 7(2). <https://doi.org/10.5210/ojphi.v7i2.5595>
- [27]. Mammì M, Citraro R, Torcasio G, Cusato G, Palleria C, Paola ED di. Pharmacovigilance in pharmaceutical companies: An overview. *Journal of Pharmacology and Pharmacotherapeutics*. 2013;4(1\_suppl): S33-S37. doi:10.4103/0976-500X.120945
- [28]. Kumar, S. & ., Badruddeen & Singh, S.P.. (2016). Pharmacovigilance: An inevitable path towards drug safety in India. *International Research Journal of Pharmacy*. 7. 1-7. 10.7897/2230-8407.0710113.
- [29]. Fernandes, Swapnil Dylan, et al. "A national approach to pharmacovigilance: The case of India as a growing hub of global clinical trials." *Research in Social and Administrative Pharmacy* 15.1 (2019): 109-113.
- [30]. Mittal, Niti, Rakesh Mittal, and M. C. Gupta. "An overview of the pharmacovigilance system in India." *Clinical research and regulatory affairs* 33.1 (2016): 4-8.
- [31]. Rukmangathen, Rajalakshmi, Brahmanapalli Vasundara Devi, and Dharini Bhoopathi. "The roles and responsibilities of pharmacovigilante's in adverse drug reaction monitoring centre." *Indian Journal of Pharmacy Practice* 10.2 (2017).
- [32]. Fukushima, Ayako, et al. "Smartphone-based mobile applications for adverse drug reactions reporting: global status and country experience." *BMC Medical Informatics and Decision Making* 22.1 (2022): 118.
- [33]. Hadi MA, Neoh CF, Zin RM, Elrggal ME, Cheema E. Pharmacovigilance: pharmacists' perspective on spontaneous adverse drug reaction reporting. *Integr Pharm Res Pract*. 2017;6:91-98 <https://doi.org/10.2147/IPRP.S105881>
- [34]. Shukla S, Gupta M, Pandit S, Thomson M, Shivhare A, Kalaiselvan V, Singh GN. Implementation of adverse event reporting for medical devices, India. *Bull World Health Organ*. 2020 Mar 1;98(3):206-211. doi: 10.2471/BLT.19.232785. Epub 2019 Nov 18. PMID: 32132755; PMCID: PMC7047028.
- [35]. Harugeri A, Shastri V, Patel C. Deriving meaningful insights from clinical trial and postmarketing safety data: Perspectives from India. *Perspect Clin Res*. 2017 Apr-Jun;8(2):68-72. doi: 10.4103/2229-3485.203046. PMID: 28447016; PMCID: PMC5384402.
- [36]. Arora D. Pharmacovigilance obligations of the pharmaceutical companies in India. *Indian J Pharmacol*. 2008 Feb;40(Suppl 1):S13-6. PMID: 21369406; PMCID: PMC3038525.
- [37]. Persaud-Sharma, V., and S. F. Zhou. "Incorporation of new technologies into global pharmacovigilance." *J Pharmacovigilance* 1 (2013): e102.
- [38]. Shin, H.; Cha, J.; Lee, C.; Song, H.; Jeong, H.; Kim, J.-Y.; Lee, S. The 2011–2020 Trends of Data-Driven Approaches in Medical Informatics for Active Pharmacovigilance. *Appl. Sci*. 2021, 11, 2249. <https://doi.org/10.3390/app11052249>
- [39]. Lavertu, Adam, et al. "A new era in pharmacovigilance: Toward real-world data and digital monitoring." *Clinical Pharmacology & Therapeutics* 109.5 (2021): 1197-1202.
- [40]. Marcel Salathé, *Digital Pharmacovigilance and Disease Surveillance: Combining Traditional and Big-Data Systems for Better Public Health*, *The Journal of Infectious Diseases*, Volume 214, Issue suppl\_4, December 2016, Pages S399–S403, <https://doi.org/10.1093/infdis/jiw281>
- [41]. Palaian, Subish. "Pharmacovigilance practices and activities: Issues, challenges, and future direction." *Social and Administrative Aspects of Pharmacy in Low-and Middle-Income Countries*. Academic Press, 2018. 145-162.
- [42]. Gawai, Pushpraj P. "Introduction and evaluation of Pharmacovigilance for beginners." (2020).
- [43]. Al Hail, Moza, et al. "Overview of pharmacovigilance practices at the largest academic healthcare system in the State of Qatar." *International journal of clinical pharmacy* 40 (2018): 769-774.



- [44]. Ampadu, H., Hoekman, J., Arhinful, D. et al. Organizational capacities of national pharmacovigilance centres in Africa: assessment of resource elements associated with successful and unsuccessful pharmacovigilance experiences. *Global Health* 14, 109 (2018). <https://doi.org/10.1186/s12992-018-0431-0>
- [45]. Nurgali, Kulmira, R. Thomas Jagoe, and Raquel Abalo. "Adverse effects of cancer chemotherapy: Anything new to improve tolerance and reduce sequelae?." *Frontiers in pharmacology* 9 (2018): 362658.
- [46]. ASHP guidelines on adverse drug reaction monitoring and reporting, *American Journal of Hospital Pharmacy*, Volume 46, Issue 2, 1 February 1989, Pages 336–337, <https://doi.org/10.1093/ajhp/46.2.336>
- [47]. Felix Wong et al. Leveraging artificial intelligence in the fight against infectious diseases. *Science* 381,164-170(2023).DOI:10.1126/science.adh1114
- [48]. Parums DV. Editorial: Infectious Disease Surveillance Using Artificial Intelligence (AI) and its Role in Epidemic and Pandemic Preparedness. *Med Sci Monit.* 2023 Jun 1;29:e941209. doi: 10.12659/MSM.941209. PMID: 37259578; PMCID: PMC10240961.
- [49]. Liang, Likeng, et al. "Artificial intelligence-based pharmacovigilance in the setting of limited resources." *Drug Safety* 45.5 (2022): 511-519.
- [50]. Hussain, Rabia. "Big data, medicines safety and pharmacovigilance." *Journal of pharmaceutical policy and practice* 14.1 (2021): 48.
- [51]. Danysz K, Cicirello S, Mingle E, Assuncao B, Tetarenko N, Mockute R, Abatamarco D, Widdowson M, Desai S. Artificial Intelligence and the Future of the Drug Safety Professional. *Drug Saf.* 2019 Apr;42(4):491-497. doi: 10.1007/s40264-018-0746-z. PMID: 30343417; PMCID: PMC6450851.
- [52]. Jaguste VS. Risk-based monitoring: Review of the current perceptions and toward effective implementation. *Perspect Clin Res.* 2019 Apr-Jun;10(2):57-61. doi: 10.4103/picr.PICR\_18\_18. PMID: 31008070; PMCID: PMC6463506.
- [53]. Kolte, Ashutosh, et al. "Ambidexterity's influence on export strategy development—The case of the Indian pharmaceutical industry." *Thunderbird International Business Review* 64.5 (2022): 465-476.
- [54]. Lamprecht, Izak van Biljon. An investigation into the prospects of existing technologies to address the challenges faced in pharmacovigilance systems. Diss. Stellenbosch: Stellenbosch University, 2018.

